News

Defective calcium clearance is a characteristic feature of early damage to the retinal ganglion cells (RGC) in a mouse model of glaucoma.

Uri Soiberman, MD, shares some key takeaways from his presentation at the inaugural IKA Keratoconus Symposium.

Patrick Yu-Wai-Man, MD, PhD, is being recognized by the ARVO Foundation for his research on gene replacement therapy for Leber hereditary optic neuropathy.

Current smokers with Graves' Disease had a greater 5-year cumulative probability, compared with patients who had never smoked, of undergoing orbital decompression.

The endothelial cells play an essential role in vision. They ensure that the cornea remains transparent by keeping it partially dehydrated.

A team of researchers used gene expression, epigenetic, and gene regulation analyses to discover genes, pathways, and regulatory features relevant to age-related macular degeneration (AMD).

According to the companies, Boehringer Ingelheim will use RetinAI’s tools to develop treatments for GA, applying the company’s artificial intelligence tools to its imaging data in a search for novel biomarkers and predictors of disease progression.

RetinAI announced their new partnership with Boehringer Ingelheim with the goal to improve patient outcomes in geographic atrophy (GA) by combining their respective expertise in artificial intelligence and retinal disease research.

Researchers at the Smurfit Institute of Genetics, in collaboration with the biotechnology company Exhaura Ltd., have shown that a gene therapy-based approach can decrease intraocular pressure in pre-clinical models of glaucoma.

Physicians are using the procedure to treat various stages of the disease.

Former smokers were at higher risk of having to undergo surgery for TED in a recent study, but the risk was lower than that associated with current smoking.

Researchers from Singapore and Sweden have found a promising stem cell approach to correct photoreceptor cell degeneration, which underlies several forms of visual decline and blindness.

According to the company, the outcomes reported demonstrate a favorable safety profile for its novel, noninvasive glaucoma treatment.

Procedure provides ophthalmologists with another treatment option.

A recent study aimed to set the record straight on the occurrence of retinal vein occlusions (RVOs) following messenger RNA COVID-19 vaccinations.

Palatin Technologies, Inc. announced manuscript publication that summarizes data demonstrating the effects of PL8331 in two mouse models of retinal disease, experimental autoimmune uveoretinitis and diabetic retinopathy.

An action filed in U.S. District Court for the Northern District of Illinois by a Pennsylvania woman alleges that neither she nor her physicians were alerted that Tepezza could result in loss of hearing or tinnitus. Horizon said in a statement this and other lawsuits are without merit.

AVA-Net is a deep-learning network developed by scientists from the University of Illinois at Chicago.

AVA-Net, a deep learning network, differentiated the changes in blood flow in healthy eyes compared with eyes of patients with diabetes with and without mild diabetic retinopathy.

The Centre for Ocular Research and Education is demonstrating its latest discoveries for eye applications at the Association for Research in Vision and Ophthalmology’s annual meeting in New Orleans.

Clearside Biomedical plans to open enrollment for their Phase 2b clinical trial of CLS-AX this quarter. Topline results are expected by the Q3 of 2024.

The company said this week it plans to open the trial for enrollment this quarter and expects topline results by the third quarter of 2024.

Reducing treatment burden, finding something other than a shot a month is key.

During a presentation at the Vit-Buckle Society meeting in Las Vegas, Sally S. Ong, MD, highlighted a new study of patients who underwent primary repair of uncomplicated RRDs at the Wilmer Eye Institute to examine the baseline, surgical and postoperative characteristics that affect best-corrected VA outcomes.

Complement Therapeutics GmbH secured financing to continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001, an AAV gene therapy for the treatment of GA secondary to dry-AMD.

Dr Ong and colleagues undertook a retrospective study of patients who underwent primary repair of uncomplicated RRDs at the Wilmer Eye Institute to examine the baseline, surgical, and postoperative characteristics that affect best-corrected VA (BCVA) outcomes.

The programme includes thousands of poster and paper presentations by up-and-coming vision scientists and world leaders in their respective subspecialties.